NZ335945A - Presenilin proteins and genetic sequences that are related to Alzheimer's disease - Google Patents

Presenilin proteins and genetic sequences that are related to Alzheimer's disease

Info

Publication number
NZ335945A
NZ335945A NZ335945A NZ33594596A NZ335945A NZ 335945 A NZ335945 A NZ 335945A NZ 335945 A NZ335945 A NZ 335945A NZ 33594596 A NZ33594596 A NZ 33594596A NZ 335945 A NZ335945 A NZ 335945A
Authority
NZ
New Zealand
Prior art keywords
alzheimer
disease
presenilin
genetic sequences
protein
Prior art date
Application number
NZ335945A
Other languages
English (en)
Inventor
St
Original Assignee
Univ Toronto
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,048 external-priority patent/US6531586B1/en
Priority claimed from US08/496,841 external-priority patent/US6210919B1/en
Application filed by Univ Toronto, Hsc Res Dev Lp filed Critical Univ Toronto
Publication of NZ335945A publication Critical patent/NZ335945A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/63—Genetically modified worms
    • A01K67/64—Genetically modified nematodes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/703—Worms, e.g. Caenorhabdities elegans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
NZ335945A 1995-04-28 1996-04-29 Presenilin proteins and genetic sequences that are related to Alzheimer's disease NZ335945A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/431,048 US6531586B1 (en) 1995-04-28 1995-04-28 Genetic sequences related to Alzheimer's Disease
US08/496,841 US6210919B1 (en) 1995-04-28 1995-06-28 Genetic sequences and proteins related to alzheimer's disease
US50935995A 1995-07-31 1995-07-31
NZ305822A NZ305822A (en) 1995-04-28 1996-04-29 Isolated presenilin genes and use in diagnosing Alzheimer's Disease

Publications (1)

Publication Number Publication Date
NZ335945A true NZ335945A (en) 2000-09-29

Family

ID=27411707

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335945A NZ335945A (en) 1995-04-28 1996-04-29 Presenilin proteins and genetic sequences that are related to Alzheimer's disease
NZ305822A NZ305822A (en) 1995-04-28 1996-04-29 Isolated presenilin genes and use in diagnosing Alzheimer's Disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ305822A NZ305822A (en) 1995-04-28 1996-04-29 Isolated presenilin genes and use in diagnosing Alzheimer's Disease

Country Status (19)

Country Link
US (9) US5986054A (enExample)
EP (2) EP2000479A1 (enExample)
JP (3) JP4504463B2 (enExample)
KR (1) KR19990008181A (enExample)
AT (1) ATE405645T1 (enExample)
AU (1) AU716307B2 (enExample)
BR (1) BR9608140A (enExample)
CA (1) CA2219214A1 (enExample)
CZ (1) CZ339097A3 (enExample)
DE (1) DE69637649D1 (enExample)
DK (1) DK0826042T3 (enExample)
ES (1) ES2314979T3 (enExample)
HU (1) HUP9801639A3 (enExample)
MX (1) MX9708270A (enExample)
NO (1) NO974964L (enExample)
NZ (2) NZ335945A (enExample)
PL (1) PL185549B1 (enExample)
SK (1) SK145397A3 (enExample)
WO (1) WO1996034099A2 (enExample)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JP4073955B2 (ja) * 1995-07-07 2008-04-09 ダーウィン モレキュラー コーポレイション アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
JP2000513923A (ja) * 1995-07-18 2000-10-24 ワシントン・ユニバーシティ 変異ｓ１８２遺伝子
WO1997007213A2 (en) * 1995-08-16 1997-02-27 President And Fellows Of Harvard College Assay for identifying genes causing chromosome non-disjunction
US6248555B1 (en) * 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US6787641B1 (en) * 1995-09-27 2004-09-07 The Trustees Of Columbia University In The City Of New York Identification of sel-12 and uses thereof
ZA968898B (en) * 1995-10-25 1998-03-30 Washington University Of Medic Method for elucidation and detection of polymorphisms, splice variants and proximal coding mutations using intronic sequences of the mutations Alzheimer's S182 gene.
JPH10327897A (ja) * 1996-01-19 1998-12-15 Washington Univ プレセニリン−１遺伝子の配列を用いる疾患の診断および予後診断
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
AU2541497A (en) * 1996-04-04 1997-10-29 Institute Of Genomic Research, The Variant presenilin-2 genes
WO1997046678A1 (en) * 1996-06-06 1997-12-11 Bayer Corporation Nucleic acids and polypeptides related to presenilin
EP0811695A3 (en) * 1996-06-06 1998-07-29 Washington University Mutant S182(PS-1) genes
EP0814157A3 (en) * 1996-06-18 1998-01-07 Smithkline Beecham Corporation Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease
AU3251997A (en) * 1996-07-05 1998-02-02 Governing Council Of The University Of Toronto, The Genetic sequences and proteins related to Alzheimer's disease, and uses herefor
WO1998025142A1 (en) 1996-12-02 1998-06-11 The Brigham And Women's Hospital, Inc. Alarm related peptides and nucleic acids and diagnosis using them
US6376239B1 (en) * 1997-04-04 2002-04-23 Elegene Gmbh DNA molecules comprising a promoter capable of conferring expression of a heterologous DNA sequence
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
AU754028B2 (en) * 1997-04-24 2002-10-31 General Hospital Corporation, The A purified 20 kDa presenilin 2 C-terminal fragment and methods of screening for compounds that inhibit proteolysis of presenilin 2
EP0981602A4 (en) * 1997-05-14 2003-01-02 Merck & Co Inc TRANSGENIC ANIMAL EXPRESSING NON-NATIVE GAME TYPE AND FAMILY ALZHEIMER DISEASE MUTED PRESENILIN-1 PROTEIN WITHOUT A BACKGROUND LEVEL OF NATIVE PRESENILIN 1
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
EP1681300A1 (en) * 1997-08-14 2006-07-19 Institut Pasteur Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS
US6284944B1 (en) * 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
FR2768346B1 (fr) 1997-09-15 2002-04-19 Fond Jean Dausset Ceph Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
FR2770217B1 (fr) * 1997-10-24 2001-12-07 Rhone Poulenc Rorer Sa Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
CZ303226B6 (cs) * 1997-10-24 2012-06-06 Aventis Pharma S. A. Zpusob detekce nebo izolace sloucenin použitelných pri lécení Alzheimerovy nemoci
AU1784499A (en) * 1998-01-08 1999-07-26 Daiichi Pharmaceutical Co., Ltd. Gene mutant animals
WO1999035501A1 (en) * 1998-01-09 1999-07-15 The Governing Council Of The University Of Toronto Presenilin protein interactions
EP1849477A1 (en) * 1998-02-25 2007-10-31 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin
EP1078987B1 (en) * 1998-05-21 2009-05-20 Mitsubishi Tanabe Pharma Corporation Method for examining central nervous system diseases and method for screening remedies
AR020329A1 (es) * 1998-07-09 2002-05-08 Boehringer Ingelheim Pharma UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C
EP1097203A1 (en) * 1998-07-16 2001-05-09 Incyte Pharmaceuticals, Inc. Human presenilin-associated protein
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6723557B1 (en) 1999-01-06 2004-04-20 California Institute Of Technology Caenorhabditis elegans LOV-1 gene
US6783982B1 (en) 1999-02-12 2004-08-31 The Governing Council Of The University Of Toronto Proteins related to neuronal regeneration and uses thereof
US6812337B1 (en) * 1999-04-01 2004-11-02 The Governing Council Of The University Of Toronto Presenilin associated membrane protein and uses thereof
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
AU4078900A (en) * 1999-04-06 2000-10-23 Harrington Arthritis Research Center Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
AU6265600A (en) * 1999-06-22 2001-01-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for detection of early-onset alzheimer's disease
DE60045005D1 (de) 1999-06-28 2010-11-04 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
US20020049303A1 (en) * 1999-06-28 2002-04-25 Tang Jordan J. N. Catalytically active recombinant memapsin and methods of use thereof
FR2798821B1 (fr) * 1999-09-27 2001-10-26 Aventis Pharma Sa Animal transgenique exprimant une forme multi-mutee de la preseniline 1
WO2001052890A1 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
MXPA02009756A (es) 2000-04-03 2003-06-17 Bristol Myers Squibb Co Aislamiento de complejo de proteina de gamma-secretasa funcionalmente activa y metodos de deteccion de la actividad e inhibidores de la misma.
AU2001264950A1 (en) * 2000-05-26 2001-12-11 Duke University Methods of screening for parkinson's disease
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US7371920B2 (en) 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
AU2001273661A1 (en) * 2000-06-30 2002-01-14 Duke University Methods of screening for alzheimer's disease
DE10032709A1 (de) * 2000-07-07 2002-01-24 Boehringer Ingelheim Pharma Aspartyl-Protease
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
JP2002142765A (ja) * 2000-07-14 2002-05-21 Tosoh Corp 新規ゲノム解析法
EP1309722A1 (en) * 2000-08-16 2003-05-14 Markus Fritzsche Use of microbial dna sequences for the identification of human diseases
AU2001287448A1 (en) * 2000-09-01 2002-03-13 The Governing Council Of The University Of Toronto Proteins related to schizophrenia and uses thereof
US6900367B2 (en) * 2000-09-29 2005-05-31 Novartis Transgenic Drosophila melanogaster expressing a β42 in the eye
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20030073608A1 (en) * 2001-04-10 2003-04-17 Woolf Nancy J. Process for treating disease
GB2375771A (en) * 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
JP2003012548A (ja) * 2001-06-27 2003-01-15 Japan Science & Technology Corp 医薬組成物
US7238798B2 (en) 2001-08-14 2007-07-03 Sentisearch, Inc. Nucleic acids and proteins of insect Or83b odorant receptor genes and uses thereof
WO2003039454A2 (en) * 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
CA2469403C (en) * 2001-12-05 2015-06-02 Jonathan Mark Boutell Protein arrays for allelic variants and uses thereof
EP1469717A4 (en) * 2001-12-20 2007-08-22 Univ California TRIPLE TRANSGENIC MOUSE MODEL FOR MORBUS ALZHEIMER
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
AU2003246380A1 (en) * 2002-07-05 2004-01-23 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
US20060183117A1 (en) * 2002-07-08 2006-08-17 Pericak-Vance Margaret A Screening for alzheimer's disease
US20040076606A1 (en) * 2002-09-14 2004-04-22 Ming-Shi Chang Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
WO2005075684A2 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier
WO2005074994A1 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Oat3 transporter expressed in blood brain barrier cells
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
WO2006086098A2 (en) * 2005-01-06 2006-08-17 President And Fellows Of Harvard College Mass spectrometric methods and products
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
US7704695B2 (en) * 2005-07-29 2010-04-27 Xenoport, Inc. Screening of compounds for BGT1 transporter activity
WO2007016161A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Oct3 transporters expressed in blood brain barrier cells
WO2007016164A2 (en) * 2005-07-29 2007-02-08 Xenoport, Inc. Cat1 transporters expressed in blood brain barrier cells
US7700300B2 (en) * 2005-07-29 2010-04-20 Xenoport, Inc. Screening of compounds for GAT2 transporter activity
US7704696B2 (en) * 2005-07-29 2010-04-27 Xenoport, Inc. Screening of compounds for OCTN2 transporter activity
AU2006279896A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
WO2007086980A2 (en) * 2005-11-10 2007-08-02 Duke University Methods of determining the risk of developing coronary artery disease
WO2007106617A2 (en) 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
JP2009533016A (ja) * 2006-02-06 2009-09-17 イーラン ファーマスーティカルズ、インコーポレイテッド プレセニリン１特異的阻害剤及びそれらの使用
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
JP2009532674A (ja) 2006-03-31 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 神経変性障害及びアルツハイマー病を治療するための、並びに正常な記憶を改善するための方法と組成物
US7771741B2 (en) * 2006-05-01 2010-08-10 Warsaw Orthopedic, Inc Demineralized bone matrix devices
EP2402449A3 (en) * 2006-05-01 2012-04-04 Aarhus Universitet An animal model and a method for producing an animal model
WO2008106981A1 (en) * 2007-03-07 2008-09-12 Aarhus Universitet Transgenic pig as a model of alzheimer's disease
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
US20140193341A1 (en) * 2011-01-19 2014-07-10 Asa Abeliovich Human induced neuronal cells
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012178183A1 (en) * 2011-06-24 2012-12-27 Board Of Regents, The University Of Texas System Human age-related neurodegenerative nematode model and methods
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
EP2791159A4 (en) * 2011-12-14 2015-10-14 Moderna Therapeutics Inc MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2530141B1 (es) * 2013-08-26 2016-01-15 Juan Carlos GALLAR RUIZ Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3438128B1 (en) * 2017-08-04 2020-05-20 Alzheimur 2012 S.L. Anti-presenilin antibody for use in the prevention and/or treatment of cancer
EP3796980A4 (en) * 2018-05-22 2022-03-23 The Brigham & Women's Hospital, Inc. NEW THERAPY FOR ALZHEIMER'S DISEASE
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2020242892A1 (en) * 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
IL293285A (en) 2019-11-29 2022-07-01 Paros Bio Inc Gene therapy for neurodegenerative disorders
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
KR102584857B1 (ko) * 2020-09-23 2023-10-06 재단법인대구경북과학기술원 알츠하이머 동물모델 및 이의 용도
KR20230009140A (ko) * 2021-07-08 2023-01-17 주식회사 엠케이바이오텍 Human mutant Presenilin-1 발현 인지장애 모델 개의 생산

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690893A (en) * 1985-05-03 1987-09-01 Dnax Research Institute Of Molecular And Cellular Biology, Inc. Hybridoma cell lines producing monoclonal antibodies which specifically bind to mouse interleukin-2
WO1988003951A1 (en) * 1986-11-17 1988-06-02 California Biotechnology, Inc. Recombinant alzheimer's amyloid protein
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
JPH05199896A (ja) * 1990-10-29 1993-08-10 Shinetsu Bio Inc モノクローナル抗体含有試薬
AU669844B2 (en) 1991-03-15 1996-06-27 Hsc Research And Development Limited Partnership Gene construct for production of transgenic fish
US5297562A (en) * 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
NZ242955A (en) * 1991-06-13 1995-01-27 Ici Plc Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code
IL105793A0 (en) * 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
CA2135313A1 (en) * 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5668006A (en) * 1992-07-17 1997-09-16 American Cyanamid Company Somatostatin receptors
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
ES2346852T3 (es) * 1992-10-26 2010-10-21 Elan Pharmaceuticals, Inc. Metodos para la identificacion de los compuestos inhibidores de la liberacion del peptido beta-amiloide (betaap).
WO1994023049A2 (en) * 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6998467B1 (en) * 1995-04-28 2006-02-14 The Hospital For Sick Children Antibody specific for presenilin 1 and method of use thereof
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6210919B1 (en) * 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6531586B1 (en) * 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
JP4073955B2 (ja) 1995-07-07 2008-04-09 ダーウィン モレキュラー コーポレイション アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
JPH11509730A (ja) * 1995-07-13 1999-08-31 ユニバーシティ・オブ・サウス・フロリダ 早発性アルツハイマー病遺伝子および遺伝子産物
JP2000513923A (ja) * 1995-07-18 2000-10-24 ワシントン・ユニバーシティ 変異ｓ１８２遺伝子
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用

Also Published As

Publication number Publication date
AU716307B2 (en) 2000-02-24
US7507798B2 (en) 2009-03-24
US6395960B1 (en) 2002-05-28
ATE405645T1 (de) 2008-09-15
BR9608140A (pt) 1999-12-07
EP0826042A2 (en) 1998-03-04
AU5394096A (en) 1996-11-18
ES2314979T3 (es) 2009-03-16
WO1996034099A2 (en) 1996-10-31
NO974964L (no) 1997-12-29
US5986054A (en) 1999-11-16
JP2013107890A (ja) 2013-06-06
US20050214837A1 (en) 2005-09-29
JP5053746B2 (ja) 2012-10-17
SK145397A3 (en) 1998-09-09
JP2007297407A (ja) 2007-11-15
US6117978A (en) 2000-09-12
KR19990008181A (ko) 1999-01-25
US20090191650A1 (en) 2009-07-30
PL185549B1 (pl) 2003-05-30
US6485911B1 (en) 2002-11-26
CZ339097A3 (cs) 1998-02-18
WO1996034099A3 (en) 1996-12-05
CA2219214A1 (en) 1996-10-31
US7838247B2 (en) 2010-11-23
EP2000479A1 (en) 2008-12-10
US6194153B1 (en) 2001-02-27
US5840540A (en) 1998-11-24
US7846679B2 (en) 2010-12-07
DK0826042T3 (da) 2008-11-24
US20080286813A1 (en) 2008-11-20
HUP9801639A3 (en) 2001-01-29
PL323109A1 (en) 1998-03-16
EP0826042B1 (en) 2008-08-20
HUP9801639A2 (hu) 1998-10-28
MX9708270A (es) 1998-06-28
NO974964D0 (no) 1997-10-27
DE69637649D1 (de) 2008-10-02
NZ305822A (en) 2000-08-25
JPH11504214A (ja) 1999-04-20
JP4504463B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
NZ335945A (en) Presenilin proteins and genetic sequences that are related to Alzheimer's disease
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
AU3056289A (en) Genetic constructs containing the alzheimer brain amyloid gene
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
CA2258502A1 (en) Modified factor viii
AU2273392A (en) Genetic sequences encoding flavonoid pathway enzymes and uses therefor
CA2177827A1 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
PL299053A1 (en) Amino acid compound being a nucleic acid, vector, host cell, genomic zyme clone, method of diagnozing the alzheimer disease, method of determining and expressing a nucleic acid sequence
OA09116A (en) Novel protein, sequences containing the gene therefore vectors, methods of preparation and use.
AU3802595A (en) Tripeptidyl aminopeptidase
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
AU8258591A (en) Human mk gene and protein sequence
AU1870597A (en) Nucleic acid sequences of genes of the high mobility group proteins and uses thereof
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
AU6724794A (en) GRB3-3 gene, its variants and their uses
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
MX9806041A (es) Proteina purificada sr-p70.
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
HU9503017D0 (en) Integrative dna segment compraising gene encoding insecticidal protein
ATE215123T1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
AU8526691A (en) Nucleotide and amino acid sequences of protein mtp40 of m. tuberculosis and synthetic peptides derived therefrom
CA2287902A1 (en) Isolated nucleic acid molecules encoding ssx family members and uses thereof

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)